Cargando…
The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial
INTRODUCTION: Current guidelines for the management of type 2 diabetes (T2D) emphasize diet as essential therapy. However, the effect of diet on systemic inflammation remains unclear. We investigated the effects of consuming a macrobiotic Ma-Pi 2 diet versus a standard recommended diet (control diet...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379741/ https://www.ncbi.nlm.nih.gov/pubmed/25852946 http://dx.doi.org/10.1136/bmjdrc-2014-000079 |
_version_ | 1782364241814093824 |
---|---|
author | Soare, Andreea Del Toro, Rossella Roncella, Elena Khazrai, Yeganeh Manon Angeletti, Silvia Dugo, Laura Fallucca, Sara Fontana, Lucia Altomare, Maria Formisano, Valeria Capata, Francesca Gesuita, Rosaria Manfrini, Silvia Fallucca, Francesco Pianesi, Mario Pozzilli, Paolo |
author_facet | Soare, Andreea Del Toro, Rossella Roncella, Elena Khazrai, Yeganeh Manon Angeletti, Silvia Dugo, Laura Fallucca, Sara Fontana, Lucia Altomare, Maria Formisano, Valeria Capata, Francesca Gesuita, Rosaria Manfrini, Silvia Fallucca, Francesco Pianesi, Mario Pozzilli, Paolo |
author_sort | Soare, Andreea |
collection | PubMed |
description | INTRODUCTION: Current guidelines for the management of type 2 diabetes (T2D) emphasize diet as essential therapy. However, the effect of diet on systemic inflammation remains unclear. We investigated the effects of consuming a macrobiotic Ma-Pi 2 diet versus a standard recommended diet (control diet) on markers of inflammation in patients with T2D. METHODS: This was a post hoc analysis of the MADIAB trial, a 21-day randomized controlled trial conducted in 51 patients (25 males and 26 females) with T2D. Patients were randomized 1:1 to the Ma-Pi 2 macrobiotic diet or a control diet based on dietary guidelines for T2D. Biological antioxidant potential of plasma and circulating levels of high-sensitivity C reactive protein, interleukin-6, tumor necrosis factor-α, and insulin-like growth factor-1 were assessed. RESULTS: After 21 days on the Ma-Pi 2 or control diet, markers of inflammation were reduced in both groups. The antioxidant potential of plasma improved significantly in the Ma-Pi group. A significant reduction in insulin growth factor-1 was observed in the Ma-Pi group versus control group (p<0.001). CONCLUSIONS: Findings of this post hoc analysis demonstrated that the Ma-Pi 2 diet is a safe dietary strategy to reduce levels of the markers of insulin resistance and inflammation, compared with baseline values, in the short term. Furthermore, the Ma-Pi 2 diet was superior to the control diet in reducing insulin growth factor-1 and may be beneficial for patients with T2D. TRIAL REGISTRATION NUMBER: Current Controlled Trials ISRCTN10467793. |
format | Online Article Text |
id | pubmed-4379741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-43797412015-04-07 The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial Soare, Andreea Del Toro, Rossella Roncella, Elena Khazrai, Yeganeh Manon Angeletti, Silvia Dugo, Laura Fallucca, Sara Fontana, Lucia Altomare, Maria Formisano, Valeria Capata, Francesca Gesuita, Rosaria Manfrini, Silvia Fallucca, Francesco Pianesi, Mario Pozzilli, Paolo BMJ Open Diabetes Res Care Perspectives in Diabetes INTRODUCTION: Current guidelines for the management of type 2 diabetes (T2D) emphasize diet as essential therapy. However, the effect of diet on systemic inflammation remains unclear. We investigated the effects of consuming a macrobiotic Ma-Pi 2 diet versus a standard recommended diet (control diet) on markers of inflammation in patients with T2D. METHODS: This was a post hoc analysis of the MADIAB trial, a 21-day randomized controlled trial conducted in 51 patients (25 males and 26 females) with T2D. Patients were randomized 1:1 to the Ma-Pi 2 macrobiotic diet or a control diet based on dietary guidelines for T2D. Biological antioxidant potential of plasma and circulating levels of high-sensitivity C reactive protein, interleukin-6, tumor necrosis factor-α, and insulin-like growth factor-1 were assessed. RESULTS: After 21 days on the Ma-Pi 2 or control diet, markers of inflammation were reduced in both groups. The antioxidant potential of plasma improved significantly in the Ma-Pi group. A significant reduction in insulin growth factor-1 was observed in the Ma-Pi group versus control group (p<0.001). CONCLUSIONS: Findings of this post hoc analysis demonstrated that the Ma-Pi 2 diet is a safe dietary strategy to reduce levels of the markers of insulin resistance and inflammation, compared with baseline values, in the short term. Furthermore, the Ma-Pi 2 diet was superior to the control diet in reducing insulin growth factor-1 and may be beneficial for patients with T2D. TRIAL REGISTRATION NUMBER: Current Controlled Trials ISRCTN10467793. BMJ Publishing Group 2015-03-26 /pmc/articles/PMC4379741/ /pubmed/25852946 http://dx.doi.org/10.1136/bmjdrc-2014-000079 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Perspectives in Diabetes Soare, Andreea Del Toro, Rossella Roncella, Elena Khazrai, Yeganeh Manon Angeletti, Silvia Dugo, Laura Fallucca, Sara Fontana, Lucia Altomare, Maria Formisano, Valeria Capata, Francesca Gesuita, Rosaria Manfrini, Silvia Fallucca, Francesco Pianesi, Mario Pozzilli, Paolo The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial |
title | The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial |
title_full | The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial |
title_fullStr | The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial |
title_full_unstemmed | The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial |
title_short | The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial |
title_sort | effect of macrobiotic ma-pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the madiab trial |
topic | Perspectives in Diabetes |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379741/ https://www.ncbi.nlm.nih.gov/pubmed/25852946 http://dx.doi.org/10.1136/bmjdrc-2014-000079 |
work_keys_str_mv | AT soareandreea theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT deltororossella theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT roncellaelena theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT khazraiyeganehmanon theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT angelettisilvia theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT dugolaura theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT falluccasara theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT fontanalucia theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT altomaremaria theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT formisanovaleria theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT capatafrancesca theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT gesuitarosaria theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT manfrinisilvia theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT falluccafrancesco theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT pianesimario theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT pozzillipaolo theeffectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT soareandreea effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT deltororossella effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT roncellaelena effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT khazraiyeganehmanon effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT angelettisilvia effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT dugolaura effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT falluccasara effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT fontanalucia effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT altomaremaria effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT formisanovaleria effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT capatafrancesca effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT gesuitarosaria effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT manfrinisilvia effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT falluccafrancesco effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT pianesimario effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial AT pozzillipaolo effectofmacrobioticmapi2dietonsystemicinflammationinpatientswithtype2diabetesaposthocanalysisofthemadiabtrial |